Cas:79539-35-8 Lucifer Yellow anhydride dipotassium salt manufacturer & supplier

Chemical Name:Lucifer Yellow anhydride dipotassium salt

CAS.NO:79539-35-8

Synonyms:4-Amino-3,6-disulfo-1,8-naphthalic anhydride dipotassium salt;4-amino-3,6-sulfo-1,8-naphthalic anhydride potassium salt;dipotassium 4-amino-3,6-disulfonaphthalic anhydride;MFCD00012400

Molecular Formula:C₁₂H₅K₂NO₉S₂

Molecular Weight:449.49600

HS Code:

Physical and Chemical Properties:

Melting point:>300ºC(lit.)

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:200.55000

Exact Mass:448.86800

LogP:2.28360

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 4-Amino-3,6-disulfo-1,8-naphthalic anhydride dipotassium salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00012400 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Amino-3,6-disulfo-1,8-naphthalic anhydride dipotassium salt Use and application,dipotassium 4-amino-3,6-disulfonaphthalic anhydride technical grade,usp/ep/jp grade.

Related News: The resort island of Jeju off the south coast of South Korea, a popular destination for Chinese tourists, is temporarily suspending the 30-day no-visa entry that it was granting to Chinese and other foreign tourists. Lucifer Yellow anhydride dipotassium salt manufacturer The vaccine significantly reduced — by 58% — the accumulation of neurofilament light chain in the blood. This is an important biomarker of neurodegenerative diseases, Novak said — damaged nerve cells release the substance, which leaks into the blood. Lucifer Yellow anhydride dipotassium salt supplier Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. Lucifer Yellow anhydride dipotassium salt vendor  The StartScore model was developed by the company��s in-house supply chain experts based on actual performance data. Lucifer Yellow anhydride dipotassium salt factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.